C. Boyd Clarke Joins Rib-X Pharmaceuticals' Board of Directors
New Haven, Connecticut. July 19, 2004 — Rib-X Pharmaceuticals, Inc.,
a privately held biotechnology company developing the next generation
of antibiotics, today announced that C. Boyd Clarke, Chairman,
President, and Chief Executive Officer of Neose Technologies Inc.
(Nasdaq: NTEC), has joined its board of directors.
"Boyd Clarke has enjoyed an extremely successful career in the biotech and pharmaceutical industries. His appointment brings extensive business acumen to our Board and completes the composition of skills we were seeking when we set out to bring together a group that encompasses a strong scientific, technology, business and financial base," said Susan Froshauer, Ph.D., President and Chief Executive Officer of Rib-X. "We have spent the past couple of years building a strong team not only internally at Rib-X, but also aligning ourselves with outside directors who have the relevant experience to help guide the Company as it develops new classes of antibiotics that overcome the challenge of multi-drug resistant bacteria. I believe we have that team in place and look forward to working with Boyd as we continue with our progress."
Mr. Clarke has spent the past eight years at the helm of several biotechnology companies and is currently Chairman, President, and Chief Executive Officer of Neose Technologies, a publicly traded biopharmaceutical company focused on the improvement of protein therapeutics; positions he has held since April, 2002. Prior thereto, Mr. Clarke was President and Chief Executive Officer of Aviron, a company developing vaccines which was acquired by MedImmune. He also served as Chairman of that company from January 2001 through March 2002. Previously, Mr. Clarke was Chief Executive Officer and President of U.S. Bioscience, Inc., a biotechnology company focused on products to treat cancer, which was also acquired by MedImmune. He served as President and Chief Operating Officer of U.S. Bioscience, Inc. from 1996 to 1998. Mr. Clarke began his pharmaceutical career at Merck & Co. where he held a number of positions including being the first President of Paster-Merieux MSD, and Vice President of Merck Vaccines. Mr. Clarke has a B.S. in Biochemistry and an M.A. in History from the University of Calgary. Mr. Clarke also serves on the Boards of QLT, Inc. and Biotechnology Industry Organization (BIO).
"I enjoy working with companies that distinguish themselves with unique proprietary technology and strong management and that seek to fulfill a vital clinical need within the industry," said C. Boyd Clarke. "I believe Rib-X has all that it takes to become a success and I look forward to lending my experience to the Company as it continues to grow."
"Boyd is a talented and experienced biopharmaceutical executive. His varied achievements at the helm of several biotechnology companies will provide Rib-X with valuable business insight and a great resource to our board," said Harry H. Penner, Jr, Chairman of the Rib-X Board of Directors.
About Rib-X Pharmaceuticals
Rib-X Pharmaceuticals, Inc. is a product-driven small-molecule drug discovery and development company focused on developing and commercializing antibiotics to treat highly-resistant bacterial infections. Based in New Haven, Connecticut, the Company has raised over $170 million and has two programs, delafloxacin and radezolid, in advanced clinical trials. In addition, a preclinical program featuring an entirely new class of broad-spectrum antibiotics with the potential to treat even highly- resistant Gram-negative infections is scheduled to begin clinical trials in 2011.
Rib-X designs and develops novel small-molecule antibiotics by leveraging the Company's Nobel Prize- winning discovery platform to perform structure-based design and optimization. While many commercially valuable classes of antibiotics bind to the bacterial ribosome, including oxazolidinones, tetracyclines and macrolides, traditional antibiotic discovery relies heavily on serendipity. Rib-X's key competitive advantage is its proprietary understanding of ribosome structure, which enables it to generate antibiotics that overcome known resistance mechanisms and have broad-spectrum activity.
Rib-X's integrated research strategy combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, thereby allowing Rib-X to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinct new antibiotic classes.
"Boyd Clarke has enjoyed an extremely successful career in the biotech and pharmaceutical industries. His appointment brings extensive business acumen to our Board and completes the composition of skills we were seeking when we set out to bring together a group that encompasses a strong scientific, technology, business and financial base," said Susan Froshauer, Ph.D., President and Chief Executive Officer of Rib-X. "We have spent the past couple of years building a strong team not only internally at Rib-X, but also aligning ourselves with outside directors who have the relevant experience to help guide the Company as it develops new classes of antibiotics that overcome the challenge of multi-drug resistant bacteria. I believe we have that team in place and look forward to working with Boyd as we continue with our progress."
Mr. Clarke has spent the past eight years at the helm of several biotechnology companies and is currently Chairman, President, and Chief Executive Officer of Neose Technologies, a publicly traded biopharmaceutical company focused on the improvement of protein therapeutics; positions he has held since April, 2002. Prior thereto, Mr. Clarke was President and Chief Executive Officer of Aviron, a company developing vaccines which was acquired by MedImmune. He also served as Chairman of that company from January 2001 through March 2002. Previously, Mr. Clarke was Chief Executive Officer and President of U.S. Bioscience, Inc., a biotechnology company focused on products to treat cancer, which was also acquired by MedImmune. He served as President and Chief Operating Officer of U.S. Bioscience, Inc. from 1996 to 1998. Mr. Clarke began his pharmaceutical career at Merck & Co. where he held a number of positions including being the first President of Paster-Merieux MSD, and Vice President of Merck Vaccines. Mr. Clarke has a B.S. in Biochemistry and an M.A. in History from the University of Calgary. Mr. Clarke also serves on the Boards of QLT, Inc. and Biotechnology Industry Organization (BIO).
"I enjoy working with companies that distinguish themselves with unique proprietary technology and strong management and that seek to fulfill a vital clinical need within the industry," said C. Boyd Clarke. "I believe Rib-X has all that it takes to become a success and I look forward to lending my experience to the Company as it continues to grow."
"Boyd is a talented and experienced biopharmaceutical executive. His varied achievements at the helm of several biotechnology companies will provide Rib-X with valuable business insight and a great resource to our board," said Harry H. Penner, Jr, Chairman of the Rib-X Board of Directors.
About Rib-X Pharmaceuticals
Rib-X Pharmaceuticals, Inc. is a product-driven small-molecule drug discovery and development company focused on developing and commercializing antibiotics to treat highly-resistant bacterial infections. Based in New Haven, Connecticut, the Company has raised over $170 million and has two programs, delafloxacin and radezolid, in advanced clinical trials. In addition, a preclinical program featuring an entirely new class of broad-spectrum antibiotics with the potential to treat even highly- resistant Gram-negative infections is scheduled to begin clinical trials in 2011.
Rib-X designs and develops novel small-molecule antibiotics by leveraging the Company's Nobel Prize- winning discovery platform to perform structure-based design and optimization. While many commercially valuable classes of antibiotics bind to the bacterial ribosome, including oxazolidinones, tetracyclines and macrolides, traditional antibiotic discovery relies heavily on serendipity. Rib-X's key competitive advantage is its proprietary understanding of ribosome structure, which enables it to generate antibiotics that overcome known resistance mechanisms and have broad-spectrum activity.
Rib-X's integrated research strategy combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, thereby allowing Rib-X to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinct new antibiotic classes.
| Public Relations |
|---|
|
Kari Watson
MacDougall BioMedical Communications 781-235-3060 kari@macbiocom.com |
| Investor Relations |
|
Sarah Cavanaugh
MacDougall BioMedical Communications 781-235-3060 scavanaugh@macbiocom.com |